688799 Hunan Warrant Pharmaceutical
- 47.71
- +0.88+1.88%
Hunan Warrant Pharmaceutical News
Warner Pharma (688799.SH): The application for listing of ipratropium bromide has been approved.
Warner Pharmaceutical Co., Ltd. (688799.SH) released an announcement that its wholly-owned subsidiary, Hunan Warner Chiral Medicine Co., Ltd.,...
Warner Pharmaceutical Factory (688799.SH) plans to raise no more than 500 million yuan through a private placement to Warner Zhi Zhen, to supplement working capital.
Warner Pharmaceuticals (688799.SH) disclosed a plan to issue A shares to specific targets in 2024. The company plans to issue stocks to Warner Zhi Zhen, a partnership controlled by Mr. Huang Bendong, the actual controller. The issue price is 34.12 yuan/share, with a quantity not exceeding 14.6542 million shares (including the number of shares). It is reported that the total amount of funds raised by the issuance of shares to specific targets will not exceed 500 million yuan (including the number of shares), and the net amount of funds raised after deducting relevant issuance expenses will be used entirely to supplement working capital.
Express News | Warner Pharmaceuticals: Developing a shareholder dividend return plan for the next three years (2024-2026).
Express News | Warner Pharmaceutical Factory plans to raise no more than 500 million yuan in funds for the Warner-Zhizhen private placement controlled by the actual controller Huang Bendong.
Warner Pharmaceuticals (688799.SH): Notice of approval of the marketing application for the API arginine ibuprofen
Warner Pharmaceuticals (688799.SH) announced that Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, accepted...
Express News | Warner Pharmaceuticals: Subsidiary drug arginine ibuprofen approved for marketing
Warrant Pharmaceutical's Unit Gets Nod to Market Benidipine Hydrochloride
Hunan Warrant Pharmaceutical's (SHA:688799) unit, Hunan Warrant Pharmaceutical Chiral Drug, received approval from China's National Medical Products Administration to market raw drug ingredient benidi
Warner Pharmaceuticals (688799.SH): Benidipine hydrochloride API received approval notice for marketing application
Gelonghui, May 27丨Warner Pharmaceuticals (688799.SH) announced that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. received the “Notice of Approval of the Marketing Application for Chemical Ingredients” of benidipine hydrochloride issued by the State Drug Administration and publicized it on the “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform of the China Drug Administration (CDE) Drug Evaluation Center (CDE). Benidipine hydrochloride is a calcium channel blocker, mainly used to treat essential hypertension and angina pectoris. Benidipine hydrochloride is combined with DHP binding sites in cell membrane voltage-dependent calcium channels to inhibit calcium ions
Warner Pharmaceuticals (688799.SH) plans to explore investment opportunities in the medical and health sector in markets such as China and Southeast Asia through funds
Warner Pharmaceuticals (688799.SH) announced that it plans to invest no more than RMB 40 million to pledge 17.9767% of the investment of Hainan Heyi Vision Private Equity Investment Fund Partnership (Limited Partnership) (“Heyi Vision”). According to reports, the fund is positioned as an early growth stage venture capital fund in the medical and health sector. It focuses on innovation and value investment in the fields of biotechnology, innovative drugs, medical services, and medical devices, and aims to invest in startups in the medical and health sector in markets such as China and Southeast Asia.
Express News | Warner Pharmaceuticals: Plans to subscribe for 17.9767% of Heyi Vision's investment of no more than 40 million yuan
Express News | Warner Pharmaceuticals: The subsidiary pharmaceutical ingredient lanthanum carbonate received a notice of approval for the listing application.
Express News | Warner Pharmaceuticals: The subsidiary pharmaceutical ingredient lanthanum carbonate received a notice of approval for the listing application
Express News | Warner Pharmaceuticals: The drug Milinone injection passed the consistent evaluation of generic drug quality and efficacy
Warner Pharmaceuticals (688799.SH): Plans to exceed 100 million yuan to participate in the establishment of Queshan Huazi
Gelonghui, April 19丨Warner Pharmaceuticals (688799.SH) announced that in order to keep up with the trend and trend of macromolecular innovative drugs becoming mainstream drug use around the world, use the investment experience and resources of professional investment institutions to explore investment opportunities in innovative application fields related to the pharmaceutical industry, strengthen the company's capabilities in macromolecular drug research and development, and actively use external talents and capital to complete the company's new drug R&D transformation and product upgrade strategy with efficiency and low risk. The company now plans to work as a limited partner, Beijing Qushan Investment Management Co., Ltd., Hunan Jinyang Investment Group The limited company and other partners signed the “”
Warner Pharmaceuticals (688799.SH): Plans to build a “Green Intelligent Manufacturing Base (Phase I) with an annual output of 3,000 tons of high-end APIs and intermediates for no more than 650 million yuan
Gelonghui, April 19 | Warner Pharmaceuticals (688799.SH) announced that based on the strategic development plan, the company plans to invest no more than 650 million yuan to build the “Green Intelligent Manufacturing Base (Phase I) Construction Project with an annual output of 3,000 tons of high-end APIs and intermediates” through Zhigen Pharmaceutical's investment of no more than 650 million yuan. After the construction of the project is completed, it will further expand the production scale of the company's high-end APIs and intermediates, enhance the company's green and intelligent manufacturing capabilities, consolidate the company's ability to integrate raw materials and formulations, lay the foundation for the domestic and international industrialization layout of the company's high-end APIs and intermediate products, and enhance the company's industrial support and profitability
Warner Pharmaceuticals (688799.SH): Net profit of 60.5531 million yuan in the first quarter increased 21.90% year-on-year
Gelonghui, April 19: Warner Pharmaceuticals (688799.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 373 million yuan, up 4.38% year on year; net profit attributable to shareholders of listed companies was 60.5531 million yuan, up 21.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.2789 million yuan, up 0.28% year on year; basic earnings per share were 0.64 yuan.
The pace of refinancing is tightening, Warner Pharmaceuticals “lost” a good opportunity to issue 700 million convertible bonds
① Of the nearly 20 products included in the company's fund-raising project, more than half faced competition from more than 3 manufacturers. ② As of April 17, the number of companies that have terminated (withdrawn or rejected) refinancing in the three markets of Shanghai, Shenzhen and North China since this year reached 38.
Approval for Warner Pharmaceuticals (688799.SH) to issue convertible corporate bonds to unspecified targets expires
Warner Pharmaceuticals (688799.SH) announced that the company is obtaining approval to issue convertible corporate bonds to unspecified targets...
Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week
Key Insights Significant control over Hunan Warrant PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 56%
Express News | Warner Pharmaceuticals: Company drug registration certificate for compound ipratropium bromide solution for inhalation
Analysis
Price Target
No Data
